Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Cash Flow (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Net Cash Flow for 4 consecutive years, with $7.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 97.38% to $7.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$345.1 million, a 252.82% decrease, with the full-year FY2024 number at $254.0 million, up 195.39% from a year prior.
  • Net Cash Flow was $7.1 million for Q3 2025 at Centessa Pharmaceuticals, up from -$60.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $269.6 million in Q3 2024 to a low of -$276.5 million in Q1 2025.
  • A 4-year average of -$36.2 million and a median of -$43.0 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: soared 934.45% in 2024, then plummeted 2656.93% in 2025.
  • Centessa Pharmaceuticals' Net Cash Flow stood at -$51.9 million in 2022, then grew by 17.25% to -$43.0 million in 2023, then surged by 65.47% to -$14.8 million in 2024, then skyrocketed by 147.65% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Net Cash Flow are $7.1 million (Q3 2025), -$60.8 million (Q2 2025), and -$276.5 million (Q1 2025).